Drug Trial Radar · NCT00048568
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Last checked: Nov 20, 2026Latest source record: Dec 5, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,250
Actual
Start
Dec 2002
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 13, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not responding to methotrexate. The safety of this treatment will also be studied. Long Term Extension: The purpose of this amendment is to provide participants who have completed the initial 12-month double-blind treatment period the opportunity to receive open label treatment with active drug treatment until abatacept is approved in the local country or until clinical development has been discontinued.
Conditions
- Rheumatoid Arthritis
Interventions
AbataceptDrug
Intravenous (IV) Solution, - Weight Titered (500 mg \< 60 kg); (750 mg 60-100 kg), )1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
MethotrexateDrug
Tablets, Oral, \>= 15 mg, weekly, 1 year
PlaceboDrug
IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169Time frame: Day 169
- Number of Participants Achieving Clinically Meaningful Improvement in Health Assessment Questionnaire (HAQ) at Day 365Time frame: Day 365
- Baseline and Mean Change From Baseline (BL) in Radiographic Erosion Score Results at Day 365Time frame: BL (Day 0), Day 365
- Participants With Deaths, Adverse Events (AEs) and SAEs in the Open-Label (OL) PeriodTime frame: Day 365 to Day 2,185
- Participants With Hematology Values Meeting the Marked Abnormality Criteria in the OL PeriodTime frame: Day 365 to Day 2,185
- Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria in the OL PeriodTime frame: Day 365 to Day 2,185
- Participants With Electrolyte Values Meeting the Marked Abnormality Criteria in the OL PeriodTime frame: Day 365 to Day 2,185
- Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting the Marked Abnormality Criteria in the OL PeriodTime frame: Day 365 to Day 2,185
- Mean BL Immunoglobulins Over Time in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093
- Mean Change From BL in Immunoglobulins in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093
- Participants With Immunogenicity to Abatacept in the Cumulative DB + OL PeriodTime frame: Day 1 to Day 1,821
- Number of Participants Experiencing Clinically Significant Changes in Vital Signs in the OL PeriodTime frame: Day 365 to Day 1,821. All changes in participant vital signs were monitored on each day of study drug administration prior to dosing and 60 minutes after dosing.
- Number of Participants Experiencing AEs of Special Interest in the OL PeriodTime frame: Day 365 to Day 2,185
- Mean BL Hematocrit in the OL PeriodTime frame: Baseline (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean Change From BL in Participant Hematocrit in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean BL Platelet Count in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean Change From BL in Participant Platelet Count in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean BL Hemoglobin, Total Protein, and Albumin in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean Change From BL in Hemoglobin, Total Protein, and Albumin in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean BL White Blood Cells in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean Change From BL in White Blood Cells in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean BL Liver Function Parameters in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean Change From BL in Liver Function Parameters in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean BL Select Laboratory Parameters in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean Change From BL in Select Laboratory Parameters in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean BL Serum Electrolytes in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
- Mean Change From BL in Serum Electrolytes in the OL PeriodTime frame: BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185
Locations
48 sites in 1 country. Site status is shown where the registry gives one.
Local Institution
Birmingham, Alabama
Local Institution
Huntsville, Alabama
Local Institution
Mobile, Alabama
Local Institution
Phoenix, Arizona
Local Institution
Scottsdale, Arizona
Local Institution
Corona, California
Local Institution
Irvine, California
Local Institution
La Jolla, California
Local Institution
Long Beach, California
Local Institution
Rancho Mirage, California
Local Institution
Aurora, Colorado
Local Institution
Colorado Springs, Colorado
Local Institution
Denver, Colorado
Local Institution
Hamden, Connecticut
Local Institution
Washington D.C., District of Columbia
Local Institution
Fort Lauderdale, Florida
Local Institution
Gainsville, Florida
Local Institution
Palm Harbor, Florida
Local Institution
Sarasota, Florida
Local Institution
St. Petersburg, Florida
Local Institution
Chicago, Illinois
Local Institution
Rockford, Illinois
Local Institution
Wichita, Kansas
Local Institution
Coeur d'Alene, Maryland
Local Institution
Cumberland, Maryland
Local Institution
Springfield, Massachusetts
Local Institution
Duluth, Minnesota
Local Institution
Lincoln, Nebraska
Local Institution
New Brunswick, New Jersey
Local Institution
Albuquerque, New Mexico
Local Institution
Albany, New York
Local Institution
Binghamton, New York
Local Institution
Mineola, New York
Local Institution
New York, New York
Local Institution
Syracuse, New York
Local Institution
The Bronx, New York
Local Institution
Wilmington, North Carolina
Local Institution
Cincinnati, Ohio
Local Institution
Oklahoma City, Oklahoma
Local Institution
Duncansville, Pennsylvania
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.